395 results on '"Callea, Vincenzo"'
Search Results
2. Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion
3. Supplementary Data from Integrative Genomics Analyses Reveal Molecularly Distinct Subgroups of B-Cell Chronic Lymphocytic Leukemia Patients with 13q14 Deletion
4. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
5. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
6. Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study
7. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
8. B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens
9. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma
10. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients
11. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
12. Familial B-cell Chronic Lymphocytic Leukemia in a Population of Patients from Southern Italy
13. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia--susceptibility loci
14. B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia
15. Splenic marginal zone lymphoma: a prognostic model for clinical use
16. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients
17. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience
18. Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL
19. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
20. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia
21. Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial
22. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
23. Additional file 1: of Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
24. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
25. High-Dose Therapy and Autologous Peripheral Blood Stem Cells Transplantation Followed by a Very Low Reduced Intensity Regimen With Fludarabine + Cyclophosphamide and Allograft Improve Complete Remission Rate in De Novo Multiple Myeloma Patients
26. IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia
27. Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma
28. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
29. Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations
30. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma
31. Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenströmʼs Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System
32. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma
33. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi
34. A STUDY OF FEASIBILITY AND TOXICITY OF MULTIPLE CYCLES OF HIGH-DOSE MELPHALAN (HDM) FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (APBSCT) IN ELDERLY PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)
35. REPEATED COURSES OF HIGH-DOSE MELPHALAN (HDM) WITH SUPPORT OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT) MAY IMPROVE PROGNOSIS IN PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM)
36. Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome
37. In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia
38. In vivo biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients
39. Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia
40. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma
41. Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial
42. More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia
43. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients
44. Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors
45. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma
46. The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair
47. B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia
48. Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi
49. Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment
50. LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.